The US FDA has extended their emergency useauthorization (EUA) for the INDICAID®
COVID-19 Rapid Antigen Test to cover serial testing for asymptomatic individuals when tested 3 times, at least 48 hours apart over five days. The update extends the use of INDICAID® as a screening test, providing an additional accurate and reliable testing option for schools, workplaces, and communities.
“It busts the myth that antigen tests could only detect symptomatic patients and shows that high-quality antigen tests can be sensitive, accurate, and reliable to be used for population screening.”
Product performance against new variants are evaluated on an ongoing basis.